Swiss National Bank Invests $5.45 Million in Erasca, Inc. $ERAS

Swiss National Bank bought a new stake in Erasca, Inc. (NASDAQ:ERAS) in the 1st quarter, HoldingsChannel.com reports. The firm bought 336,800 shares of the company’s stock, valued at approximately $5,449,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ERAS. AQR Capital Management LLC raised its stake in Erasca by 594.8% during the 1st quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock worth $543,000 after buying an additional 339,177 shares during the period. Geode Capital Management LLC boosted its holdings in Erasca by 1.6% in the second quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company’s stock worth $6,143,000 after acquiring an additional 77,790 shares in the last quarter. Creative Planning grew its stake in Erasca by 423.3% in the second quarter. Creative Planning now owns 244,332 shares of the company’s stock valued at $310,000 after acquiring an additional 197,637 shares during the period. New York State Common Retirement Fund grew its stake in Erasca by 39.1% in the second quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock valued at $47,000 after acquiring an additional 10,501 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Erasca by 51.6% during the second quarter. Invesco Ltd. now owns 172,226 shares of the company’s stock valued at $219,000 after acquiring an additional 58,643 shares in the last quarter. 67.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ERAS. HC Wainwright reaffirmed a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. HSBC set a $20.00 price target on shares of Erasca in a research report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Erasca in a report on Thursday, June 11th. Wolfe Research set a $16.00 price objective on shares of Erasca in a research note on Thursday, June 4th. Finally, Bank of America raised their price objective on shares of Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday, July 14th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.64.

Erasca Price Performance

Shares of ERAS stock opened at $18.16 on Wednesday. The firm has a 50-day moving average of $15.76 and a 200-day moving average of $14.19. Erasca, Inc. has a one year low of $1.33 and a one year high of $24.28. The company has a market cap of $5.65 billion, a P/E ratio of -19.53 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, research analysts expect that Erasca, Inc. will post -0.54 earnings per share for the current fiscal year.

More Erasca News

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: No new business, clinical, regulatory, or financing developments were reported in these articles that would provide a clear near-term positive catalyst for Erasca (ERAS).
• Neutral Sentiment: Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, generally have until August 10, 2026, to seek appointment as lead plaintiff. The notices are solicitations from law firms and do not establish that the allegations are proven. Rosen Law Firm investor deadline notice
• Negative Sentiment: Multiple firms announced or promoted a class action alleging that Erasca and certain executives misled investors about ERAS-0015’s competitive performance, safety profile, patent protection, and intellectual-property advantage. The complaints point to April 27–28 disclosures involving patent-infringement allegations from a competitor and Erasca’s acknowledgment that some product comparisons were not based on head-to-head trials. One notice also says a $258.8 million offering preceded a reported 53.9% stock decline. The repeated announcements increase visibility around potential damages, governance concerns, and litigation costs, weighing on the stock. Levi and Korsinsky shareholder alert

Erasca Company Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.